(Q52007813)

19 April 2018

title

Alefacept therapy produces remission for patients with chronic plaque psoriasis (English)

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

3 January 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

3 January 2024

2

C. N. Ellis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752139

3 January 2024

author name string

G. G. Krueger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752139

3 January 2024

language of work or name

English

0 references

publication date

1 April 2003

1 reference

19 April 2018

full work available at URL

http://deepblue.lib.umich.edu/bitstream/2027.42/75170/1/j.1365-2133.2003.05239.x.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752139

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2133.2003.05239.x

3 January 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2133.2003.05239.x/fullpdf

3 January 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

British Journal of Dermatology

3 January 2024

published in

1 reference

19 April 2018

volume

148

1 reference

19 April 2018

issue

4

1 reference

19 April 2018

page(s)

784-788

1 reference

19 April 2018

Biologic therapy for psoriasis: the new therapeutic frontier

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

The risk of melanoma in association with long-term exposure to PUVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

LIFE-THREATENING PSORIASIS RELAPSE ON WITHDRAWAL OF CYCLOSPORIN

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

Generalized pustular psoriasis developing during withdrawal of short-term cyclosporin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris. Evidence that epidermal immunocytes are direct therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

PUVA and cancer risk: the Swedish follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

Treatment of plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05239.X

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

Risk of relapse upon withdrawal of cyclosporin therapy for psoriasis

3 January 2024

2

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

Cyclosporine in the treatment of dermatologic disease: an update

3 January 2024

4

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

Duration of remission of psoriasis therapies

3 January 2024

8

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris

3 January 2024

9

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

3 January 2024

Journal of Immunology

18

140

1401

Sanders ME

1988

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

3 January 2024

Therapeutic immunology

20

1

205

Chisholm PL

1994

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

3 January 2024

Journal of Immunology

21

152

2753

Majeau GR

1994

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

3 January 2024

27

1 reference

https://api.crossref.org/works/10.1046/J.1365-2133.2003.05239.X

3 January 2024

Identifiers

1 reference

19 April 2018

1 reference

19 April 2018